ReSPECT-LM Data from SNO/ASCO

by | Aug 12, 2024 | LM

Highlights include: > Respect-LM dosing shows continued feasibility and safety of up to 44 mCi of intrathecal Rhenium (186Re) Obisbemeda > High absorbed radiation doses, mean circulating tumor cell reductions, and median overall survival of 12 months continue to...

OSU for ReSPECT-LM

by | Jun 27, 2024 | LM

❗NEW CLINICAL TRIAL INVESTIGATION SITE❗ We are pleased to announce the addition of Ohio State University in Columbus, Ohio to our ReSPECT-LM Clinical Trial with Principal Investigator Shirley Ong M.D.. This site is NOW ENROLLING patients. Learn More about Dr. Ong:...

Brain & Spine Metastasis Awareness Month

by | Jun 19, 2024 | LM

June is Brain & Spine Metastasis Awareness Month! 🧠🎗️ We want to continue to raise awareness for Leptomeningeal Metastases, which is diagnosed in approximately 110,000 cases per year in the U.S. Learn more about this metastatic cancer by visiting our Comprehensive...

LM Diagnostic Assay

by | May 15, 2024 | LM

“Leptomeningeal metastases (LM) is significantly underdiagnosed because current tests such as MRI and cytology lack sensitivity,” said Priya U. Kumthekar, M.D., Associate Professor of Neurology (Neuro-oncology) and Medicine (Hematology and Oncology) at Northwestern...

LM Acquistition Meeting

by | May 9, 2024 | LM

Plus Therapeutics provided highlights regarding Leptomeningeal Metastases acquisition and topline clinical trial data on the FORESEE Trial on this morning’s investor call. Listen to the Replay: https://edge.media-server.com/mmc/p/nor9kmxs/ Highlights:...

ReSPECT-LM at North Shore

by | May 2, 2024 | LM

❗NEW CLINICAL TRIAL INVESTIGATION SITE❗ We are pleased to announce the addition of North Shore University Hospital in New York to our ReSPECT-LM Clinical Trial with Principal Investigator Michael Schulder, M.D.. This site is NOW ENROLLING patients. Michael Schulder,...